Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ascletis

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

- PMLiVE

Armoured CAR ‘could overwhelm solid tumour resistance’

Eureka Therapeutics and Memorial Sloan Kettering approach shows promise

- PMLiVE

Cancer immunotherapy: What’s on the horizon?

Old and new therapies

- PMLiVE

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

- PMLiVE

China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market

- PMLiVE

Vyriad inks immunotherapy alliance with Merck/Pfizer

Genetically engineered virus produces immune response in tumours

- PMLiVE

Christina Coughlin to leave Immunocore for Tmunity

UPenn pioneers building their own biotech company

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links